Trial · NCT06090227
AMPK-activation by Metformin in FSGS: AMP-FSGS
NCT06090227, Phase 1, Phase 2, Recruiting, Yale University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AMPK-activation by Metformin in FSGS: AMP-FSGS. Trials, record NCT06090227. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06090227
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AMPK-activation by Metformin in FSGS: AMP-FSGS
- NCT number
- NCT06090227
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Yale University
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Metformin + Standard of Care, Placebo + Standard of Care
- First posted
- 2023-10-19
- Last updated
- 2026-02-03
Source ClinicalTrials.gov
Registered outcomes31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Slope of urinary NPHS2:Creatinine ratio | 6 months following randomization | Measure of podocinuria via evaluation of urine podocin mRNA(nphs2) (measured as number of molecules detected by qPCR in the collected urine pellet) over the creatinine concentration. Intended for evaluation of efficacy of metformin versus placebo. |
| Secondary | estimated Glomerular Filtration Rate (eGFR) | 6 months post-randomization | Calculated from serum creatinine (mg/dl) using the CKD-EPI formula. Intended for evaluation of efficacy of metformin versus placebo. |
| Secondary | Slope of eGFR | 6 months post-randomization | Change in eGFR from randomization to 6 months by incorporating eGFR at all timepoints in study between baseline and 6 months post-randomization. eGFR calculated from serum creatinine (mg/dl) using the CKD-EPI formula. Intended for evaluation of efficacy of metformin versus placebo. |
| Secondary | Urine protein:creatinine ratio | 6 months post-randomization | Calculated ratio of urine protein and creatinine, each collected from the electronic medical record. Intended for evaluation of clinical efficacy of metformin versus placebo. |
| Secondary | Slope of urine protein:creatinine ratio | 6 months post-randomization | Change in urine protein:creatinine ratio from randomization to 6 months by incorporating urine protein:creatinine ratio at all timepoints in study between baseline and 6 months post-randomization. Intended for evaluation of clinical efficacy of metformin versus placebo. |
| Secondary | Complete remission | 6 months post-randomization | Calculated as the number of patients in complete remission, defined as \<0.5 gm urine protein excretion over 24 hours, or urine protein creatinine ratio \< 0.5 at 6 months post-randomization. Intended for evaluation of clinical efficacy of metformin versus placebo. |
| Secondary | Complete or partial remission | 6 months post-randomization | Calculated as the number of patients with complete remission (defined as \<0.5 gm urine protein excretion over 24 hours, or urine protein creatinine ratio \< 0.5) or partial remission (\>50% reduction in proteinuria from pre-randomization). Intended for evaluation of clinical efficacy of metformin versus placebo. |
| Secondary | Discontinuation of study drug | Within 6 months post-randomization | Number of patients who discontinued study drug for any reason within 6 months of randomization. Intended for evaluation of patient compliance of metformin use. |
| Secondary | Modified Kidney Disease Quality of Life (KDQOL) score | 1 month post-randomization | Calculated as the mean (standard deviation) of all total scores. Total scores are calculated by combining scores of 8 subsections of the KDQOL, and range from 0 - 163, with higher scores representing better quality of life. Intended for evaluation of adverse effects of metformin versus placebo. |
| Secondary | Modified Kidney Disease Quality of Life (KDQOL) score | 6 months post-randomization | Calculated as the mean (standard deviation) of all total scores. Total scores are calculated by combining scores of 8 subsections of the KDQOL, and range from 0 - 163, with higher scores representing better quality of life. Intended for evaluation of adverse effects of metformin versus placebo. |
1 to 10 of 31Source ClinicalTrials.gov
See all 31 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06090227
GET https://conductscience.org/api/trials/v1/NCT06090227/registered?page=2